BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32130793)

  • 1. Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma.
    Jiang DM; Suzuki C; Espin-Garcia O; Lim CH; Ma LX; Sun P; Sim HW; Natori A; Chan BA; Moignard S; Chen EX; Liu G; Swallow CJ; Darling GE; Wong R; Jang RW; Elimova E
    Cancer Med; 2020 May; 9(9):3023-3032. PubMed ID: 32130793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrence following curative intended surgery for an adenocarcinoma in the gastroesophageal junction: a retrospective study.
    Belmouhand M; Svendsen LB; Kofoed SC; Normann G; Baeksgaard L; Achiam MP
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?
    Kneuertz PJ; Hofstetter WL; Chiang YJ; Das P; Blum M; Elimova E; Mansfield P; Ajani J; Badgwell B
    Ann Surg Oncol; 2016 Feb; 23(2):626-32. PubMed ID: 26564243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative follow-up programs improve survival in curatively resected gastric and junctional cancer patients: a propensity score matched analysis.
    Sisic L; Strowitzki MJ; Blank S; Nienhueser H; Dorr S; Haag GM; Jäger D; Ott K; Büchler MW; Ulrich A; Schmidt T
    Gastric Cancer; 2018 May; 21(3):552-568. PubMed ID: 28741059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
    Sudarshan M; Alcindor T; Ades S; Aloraini A; van Huyse M; Asselah J; David M; Frechette D; Brisson S; Thirlwell M; Ferri L
    Ann Surg Oncol; 2015 Jan; 22(1):324-30. PubMed ID: 25023544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road.
    Depypere L; Lerut T; Moons J; Coosemans W; Decker G; Van Veer H; De Leyn P; Nafteux P
    Dis Esophagus; 2017 Jan; 30(1):1-8. PubMed ID: 27704661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan.
    Hosokawa Y; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kato Y; Daiko H; Nishimura M; Katsumata K; Sugiyama Y; Kinoshita T
    Ann Surg Oncol; 2012 Feb; 19(2):677-83. PubMed ID: 21822549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.
    Park DJ; Yoon C; Thomas N; Ku GY; Janjigian YY; Kelsen DP; Ilson DH; Goodman KA; Tang LH; Strong VE; Coit DG; Yoon SS
    Ann Surg Oncol; 2014 Apr; 21(4):1130-7. PubMed ID: 24370903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
    Cohen DJ; Newman E; Iqbal S; Chang RY; Potmesil M; Ryan T; Donahue B; Chandra A; Liu M; Utate M; Hiotis S; Pachter LH; Hochster H; Muggia F
    Ann Surg Oncol; 2012 Feb; 19(2):478-85. PubMed ID: 21769462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, efficacy, and long-term follow-up evaluation of perioperative epirubicin, Cisplatin, and capecitabine chemotherapy in esophageal resection for adenocarcinoma.
    van der Sluis PC; Ubink I; van der Horst S; Boonstra JJ; Voest EE; Ruurda JP; Borel Rinkes IH; Wiezer MJ; Schipper ME; Siersema PD; Los M; Lolkema MP; van Hillegersberg R
    Ann Surg Oncol; 2015 May; 22(5):1555-63. PubMed ID: 25564156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
    Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
    Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
    Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
    J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence in follow-up and prognosis of esophagogastric junction cancer.
    Sanz Álvarez L; Turienzo Santos E; Rodicio Miravalles JL; Moreno Gijón M; Amoza Pais S; Sanz Navarro S; Rizzo Ramos A
    Cir Esp (Engl Ed); 2019 Oct; 97(8):465-469. PubMed ID: 31060735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma.
    Fields RC; Strong VE; Gönen M; Goodman KA; Rizk NP; Kelsen DP; Ilson DH; Tang LH; Brennan MF; Coit DG; Shah MA
    Br J Cancer; 2011 Jun; 104(12):1840-7. PubMed ID: 21610705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of surveillance following curative intent therapy for gastroesophageal cancer.
    Peixoto RD; Lim HJ; Kim H; Abdullah A; Cheung WY
    J Gastrointest Cancer; 2014 Sep; 45(3):325-33. PubMed ID: 24756830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extranodal metastasis is a powerful prognostic factor in patients with adenocarcinoma of the esophagogastric junction.
    Zhang HD; Tang P; Duan XF; Chen CG; Ma Z; Gao YY; Zhang H; Yu ZT
    J Surg Oncol; 2013 Dec; 108(8):542-9. PubMed ID: 24018956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What to do after R1-resection of adenocarcinomas of the esophagogastric junction?
    Gertler R; Richter J; Stecher L; Nitsche U; Feith M
    J Surg Oncol; 2016 Sep; 114(4):428-33. PubMed ID: 27333949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment.
    Jeene PM; Versteijne E; van Berge Henegouwen MI; Bergmann JJ; Geijsen ED; Muller K; van Laarhoven HW; Hulshof MC
    Dis Esophagus; 2017 Feb; 30(2):1-5. PubMed ID: 27766725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors predicting recurrence in patients with Siewert type II carcinoma treated with curative resection.
    Fukuchi M; Mochiki E; Suzuki O; Ishiguro T; Sobajima J; Onozawa H; Imaizumi H; Shibata K; Saito K; Naitoh H; Kumagai Y; Ishibashi K; Ishida H
    Anticancer Res; 2015 Jan; 35(1):505-9. PubMed ID: 25550595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum].
    Zhu Z; Wang Y; Li F; Gao J; Han B; Wang R; Xue Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):149-155. PubMed ID: 30799537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.